GANX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GA

Mkt Cap

$54.9M

Volume

446.81K

Next Earnings

November 11th

Loading chart

GA

GANXGain Therapeutics, Inc. Common Stock

GANX

Pay with—

Available Balance0.00

GA

Mkt Cap

$58.0M

Volume

446.81K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement DisordersGain Therapeutics announced a poster presentation of long-term open-label data on its lead drug candidate rexaceract (GT-02287), a GCase modulator for Parkinson's disease treatment, at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, Korea on October 7, 2026. The presentation will showcase clinical trial results from the ongoing Phase 1b study evaluating safety and tolerability in people with PD with or without GBA1 mutations.GlobeNewswire Inc. · Sep 29, 2026

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment ConferenceGain Therapeutics announced that CEO Gene Mack will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16, 2026) in New York City. The company will provide an on-demand presentation on September 11, 2026. Gain is a clinical-stage biotech company developing allosteric small molecule therapies, with its lead candidate rexaceract currently in Phase 1b trials for Parkinson's disease treatment.GlobeNewswire Inc. · Aug 25, 2026

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitGain Therapeutics announced that President and CEO Gene Mack will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15-16, 2026. The clinical-stage biotech company is advancing its lead candidate GT-02287 for Parkinson's disease treatment in a Phase 1b clinical trial.GlobeNewswire Inc. · Jun 10, 2026

Gain Therapeutics to Present at the 38th Annual ROTH ConferenceGain Therapeutics announced that CEO Gene Mack will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026. The company will also present additional clinical and biomarker data from its Phase 1b study of GT-02287 for Parkinson's disease at AD/PD 2026, including interim analysis results. The company remains on track to initiate Phase 2 clinical trials.GlobeNewswire Inc. · Mar 19, 2026

Gain Therapeutics to Attend the 2025 Maxim Growth SummitGain Therapeutics will participate in the 2025 Maxim Growth Summit, with CEO Gene Mack joining a panel discussion on neurodegenerative diseases and presenting their lead drug candidate GT-02287 for Parkinson's disease treatment.GlobeNewswire Inc. · Oct 16, 2025

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy VolunteersGain Therapeutics presented positive Phase 1 data for its lead drug candidate GT-02287, which showed an increase in GCase activity in healthy volunteers, supporting its potential as a disease-modifying treatment for Parkinson's disease.GlobeNewswire Inc. · Sep 30, 2024

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s DiseaseGain Therapeutics, a clinical-stage biotechnology company, will host a webinar to discuss positive results from a Phase 1 study of its lead drug candidate GT-02287 for Parkinson's disease and the design of an upcoming Phase 1b trial.GlobeNewswire Inc. · Sep 26, 2024

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024Gain Therapeutics announced that it will present preclinical data on its lead drug candidate GT-02287 for the treatment of Parkinson's disease, including two late-breaking posters, at the Neuroscience 2024 conference.GlobeNewswire Inc. · Sep 19, 2024

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Autonomix Medical (NASDAQ:AMIX), Absci ... - BenzingaSeveral healthcare stocks saw significant price movements in Thursday's pre-market session, with notable gainers including Autonomix Medical, Inspire Veterinary, and Salarius Pharmaceuticals, while Gain Therapeutics, Senti Biosciences, and Aspira Womens Health declined.Benzinga · Jul 4, 2024

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open.GlobeNewswire Inc. · Jun 28, 2024

to start trading

GA

GANXGain Therapeutics, Inc. Common Stock

GANX

Pay with—

Available Balance0.00

Your PositionYou don't own any GANX yet.

Related Tickers

Earnings